Costunolide alleviated DDC induced ductular reaction and inflammatory response in murine model of cholestatic liver disease

10.1016/j.jtcme.2023.02.008

Juan Hao；Xiaoyu Shen；Kan Lu；Yi Xu；Yiyue Chen；Jibo Liu；Xiaohong Shao；Chunling Zhu；Yaqin Ding；Xin Xie；Jian Wu；Quanjun Yang

Costunolide ； Cholestatic liver disease ； Bile acid metabolism ； Inflammatory response ； Ductular reaction

Journal of Traditional and Complementary Medicine

13卷4期（2023 / 07 / 01）

345 - 357

英文

Purpose: Cholestatic liver diseases are groups of hepatobiliary diseases without curative drug-based therapy options. Regulation of bile acid (BA) metabolism, hepatoperiductal fibrosis, and inflammatory response indicated present novel methods for the treatment of cholestatic liver disease. Costunolide (COS) from herb Saussurea lappa exerts a pharmacological effect of regulation of BA metabolism, liver fbrosis and inflammatory response. The present study aimed to clarify the pharmacodynamic effects of COS against the murine model of cholestatic liver disease. Methods: We established a murine model of cholestatic liver disease through chronic feeding of 3,5- diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 28 days. Two independent in vivo experiments were designed to reveal the pharmacological effect of COS against cholestatic liver disease. In the first experiment, two dosages of COS (10 and 30 mg/kg) were intraperitoneally injected into model mice daily for 14 days. In the second experiment, high dosage of COS (30 mg/kg) was intraperitoneally injected into control and model mice daily for 28 days. Results: In the evaluation of the hepatoprotective effect of COS, COS showed dosage-dependent improvement of cholestatic liver disease, including ductular reaction, hepatoperiductal fibrosis, and inflammatory response. The mechanism of COS-mediated hepatoprotective effects mainly relies on the regulation of BA metabolism, and the inflammatory response. DDC diet feed induced hepatic BA metabolism, transport and circulation dysfunction. COS treatment not only regulated the BA metabolism and transport gene, but also reprogrammed hepatic primary and secondary BA concentrations. DDC induced hepatic infiltrated monocytes derived macrophages and lymphocytes were inhibited, while Kupffer cells were preserved by COS treatment. The liver elevating inflammatory cytokines of DDC diet feed were alleviated by COS. Moreover, high dosage of 30 mg/kg COS treatment for 28 days resulted in no significant serological changes and no obvious hepatic histopathological changes when compared with control mice. Conclusion: COS protected against DDC diet feeding-induced cholestatic liver disease since COS regulated BA metabolism, ductular reaction, hepatoperiductal fibrosis and inflammatory response. COS is suggested as a potential natural product for the treatment of cholestatic liver disease.

1. Panyod, S,Sheen, LY(2020).Beneficial effects of Chinese herbs in the treatment of fatty liver diseases.J. Tradit. Compl. Med.,10(3),260-267.
   連結：
2. Paulo, RF,Zhang, QC(2022).Liver and gall bladder channel parallels in the Hippocratic corpus and Huang Di Nei Jing with theoretical considerations.J. Tradit. Compl. Med.,12(4),384-390.
   連結：
3. Prommaouan, S,Nernpermpisooth, N,Pengnet, S,Paseephol, T,Tunsophon, S,Malakul, W(2022).Wax apple (Syzygium samarangense) fruit extract ameliorates endothelial dysfunction and liver damage in high cholesterol diet-fed rats.J. Tradit. Compl. Med.,12(6),584-593.
   連結：
4. Allen, K,Jaeschke, H,Copple, BL(2011).Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis.Am J Pathol,178(1),175-186.
5. Ban, D,Hua, S,Zhang, W,Shen, C,Miao, X,Liu, W(2019).Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2.Cell Mol Biol Lett,24(1),1-10.
6. Best, J,Verhulst, S,Syn, WK(2016).Macrophage depletion attenuates extracellular matrix deposition and ductular reaction in a mouse model of chronic chol-angiopathies.PLoS One,11(9),e0162286.
7. Boyer, JL,Soroka, CJ(2021).Bile formation and secretion: an update.J Hepatol,75(1),190-201.
8. Butturini, E,Di Paola, R,Suzuki, H(2014).Costunolide and Dehydrocostuslactone, two natural sesquiterpene lactones, ameliorate the inflammatory process associated to experimental pleurisy in mice.Eur J Pharmacol,730,107-115.
9. Cariello, M,Gadaleta, RM,Moschetta, A(2022).The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.Curr Opin Gastroenterol,38(2),136-143.
10. Chen, RJ,Wu, HH,Wang, YJ(2015).Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.Arch Toxicol,89(10),1727-1750.
11. Chiang, JYL(2017).Bile acid metabolism and signaling in liver disease and therapy.Liver Res,1(1),3-9.
12. Cossarizza, A,Chang, HD,Radbruch, A(2021).Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).Eur J Immunol,51(12),2708-3145.
13. De Martin, S,Bonaiuto, E,Gabbia, D(2021).Drug-Induced Cholangiopathies.Diseases Of the Liver And Biliary Tree
14. de Vries, E,Bolier, R,Goet, J(2021).Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial.Gastroenterology,160(3),734-743 e736.
15. Fickert, P,Stoger, U,Fuchsbichler, A(2007).A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.Am J Pathol,171(2),525-536.
16. Fuchs, CD,Trauner, M(2022).Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.Nat Rev Gastroenterol Hepatol,1-19.
17. Ge, Mx,Liu, Ht,Zhang, N(2020).Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation.Br J Pharmacol,177(2),372-387.
18. Glaser, F,John, C,Engel, B(2019).Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.J Hepatol,71(4),783-792.
19. Gong, Z,Zhou, J,Zhao, S(2016).Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.Oncotarget,7(51),83951-83963.
20. Guillot, A,Guerri, L,Feng, D(2021).Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin alphavbeta6 upregulation following liver injury.J Clin Invest,131(9)
21. Gulamhusein, AF,Hirschfield, GM(2020).Primary biliary cholangitis: pathogenesis and therapeutic opportunities.Nat Rev Gastroenterol Hepatol,17(2),93-110.
22. Jin, X,Wang, C,Wang, L(2020).Costunolide inhibits osteosarcoma growth and metastasis via suppressing STAT3 signal pathway.Biomed Pharmacother ,121,109659.
23. Karpen, SJ(2020).Pediatric cholestasis: epidemiology, genetics, diagnosis, and current management.Clin Liver Dis,15(3),115.
24. Kim, DY,Choi, BY(2019).Costunolide-A bioactive sesquiterpene lactone with diverse therapeutic potential.Int J Mol Sci,20(12)
25. Kjaergaard, K,Frisch, K,Sorensen, M(2021).Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.J Hepatol,74(1),58-65.
26. Kohara, H,Bajaj, P,Yamanaka, K(2020).High-throughput screening to evaluate inhibition of bile acid transporters using human hepatocytes isolated from chimeric mice.Toxicol Sci : Off J Soc Toxicol,173(2),347-361.
27. Kunst, RF,Niemeijer, M,van der Laan, LJW,Spee, B,van de Graaf, SFJ(2020).From fatty hepatocytes to impaired bile flow: matching model systems for liver biology and disease.Biochem Pharmacol,180,114173.
28. Lazaridis, KN,Strazzabosco, M,Larusso, NF(2004).The cholangiopathies: disorders of biliary epithelia.Gastroenterology,127(5),1565-1577.
29. Li, R,Hovingh, MV,Koehorst, M(2022).Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition.Biochim Biophys Acta, Mol Cell Biol Lipids,159163.
30. Li, WK,Wang, GF,Wang, TM(2019).Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice.Phytomedicine : Int J Phytother Phytopharmacol,62,152948.
31. Liu, B,Zhang, X,Zhang, FC,Zong, JB,Zhang, W,Zhao, Y(2013).Aberrant TGF-beta1 signaling contributes to the development of primary biliary cirrhosis in murine model.World J Gastroenterol,19(35),5828-5836.
32. Liu, Z,Gu, Y,Shin, A,Zhang, S,Ginhoux, F(2020).Analysis of myeloid cells in mouse tissues with flow cytometry.STAR Protocols,1(1),100029.
33. Mao, J,Zhan, H,Meng, F(2022).Costunolide protects against alcohol-induced liver injury by regulating gut microbiota, oxidative stress and attenuating inflammation in vivo and in vitro.Phytother Res,36(3),1268-1283.
34. Mariotti, V,Cadamuro, M,Spirli, C,Fiorotto, R,Strazzabosco, M,Fabris, L(2019).Animal models of cholestasis: an update on inflammatory cholangiopathies.Biochim et Biophys Acta Mol Basis Dis,1865(5),954-964.
35. Mariotti, V,Strazzabosco, M,Fabris, L,Calvisi, DF(2018).Animal models of biliary injury and altered bile acid metabolism.Biochim et Biophys Acta Mol Basis Dis,1864(4 Pt B),1254-1261.
36. Matsuda, H,Shimoda, H,Ninomiya, K,Yoshikawa, M.(2002).Inhibitory mechanism of costunolide, a sesquiterpene lactone isolated from Laurus nobilis, on blood-ethanol elevation in rats: involvement of inhibition of gastric emptying and increase in gastric juice secretion.Alcohol Alcohol,37(2),121-127.
37. Meng, F,Zong, W,Wei, X(2021).Dolomiaea souliei ethyl acetate extract protected against alpha-naphthylisothiocyanate-induced acute intrahepatic cholestasis through regulation of farnesoid x receptor-mediated bile acid metabolism.Phytomedicine : Int J Phytother Phytopharmacol,87,153588.
38. Nevens, F(2018).Durable response in the markers of cholestasis through 36 months of open label extension study of obeticholic acid in primary biliary cholangitis.J Hepatol,68(6),S224-S225.
39. Peng, S,Hou, Y,Yao, J,Fang, J(2019).Activation of Nrf2 by costunolide provides neuroprotective effect in PC12 cells.Food Funct,10(7),4143-4152.
40. Pose, E,Sancho-Bru, P,Coll, M(2019).3,5-Diethoxycarbonyl-1,4-Dihydrocollidine diet: a rodent model in cholestasis research.Methods Mol Biol,1981,249-257.
41. Sato, K,Glaser, S,Kennedy, L(2019).Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.Expert Opin Ther Targets,23(6),461-472.
42. Takamura, M,Matsuda, Y,Kimura, N(2021).Changes in disease characteristics of primary biliary cholangitis: an observational retrospective study from 1982 to 2016.Hepatol Res : Off J Jpn Soc Hepatol,51(2),166-175.
43. Tam, PK,Yiu, RS,Lendahl, U,Andersson, ER(2018).Cholangiopathies-towards a molecular understanding.EBioMedicine,35,381-393.
44. Trussoni, CE,O’Hara, SP,LaRusso, NF(2022).Cellular senescence in the chol-angiopathies: a driver of immunopathology and a novel therapeutic target.Semin Immunopathol,44(4),527-544.
45. Wada, K,Ueda, N,Sawada, H,Amemiya, N,Haga, M(1997).Inductive effects of bay leaf and its component costunolide on the mouse liver glutathione S-transferase.Nat Med.,51,283-285.
46. Wang, Y,Zhang, X,Zhao, L(2017).Costunolide protects lipopolysaccharide/d-galactosamine-induced acute liver injury in mice by inhibiting NF-kappaB signaling pathway.J Surg Res,220,40-45.
47. Wen, M,Liu, Y,Chen, R(2021).Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis.Phytother Res,35(7),3799-3811.
48. Wu, N,Meng, F,Invernizzi, P(2016).The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-beta1 biliary secretion in mice.Hepatology,64(3),865-879.
49. Xing, W,Wen, C,Wang, D(2022).Cardiorenal protective effect of costunolide against doxorubicin-induced toxicity in rats by modulating oxidative stress, inflammation and apoptosis.Molecules,27(7)
50. Xue, H,Fang, S,Zheng, M(2021).Da-Huang-Xiao-Shi decoction protects against3, 5-diethoxycarbonyl-1,4-dihydroxychollidine-induced chronic cholestasis by upregulating bile acid metabolic enzymes and efflux transporters.J Ethnopharmacol,269,113706.
51. Yang, H,Duan, Z(2016).Bile acids and the potential role in primary biliary cirrhosis.Digestion,94(3),145-153.
52. Yang, R,Zhao, Q,Hu, DD,Xiao, XR,Huang, JF,Li, F(2018).Metabolomic analysis of cholestatic liver damage in mice.Food Chem Toxicol : Int J Publ Br Ind Biol Res Assoc.,120,253-260.
53. Zhu, C,Fuchs, CD,Halilbasic, E,Trauner, M(2016).Bile acids in regulation of inflammation and immunity: friend or foe?.Clin Exp Rheumatol,34(4 Suppl 98),25-31.